PRIMARY ANTIPHOSPHOLIPID SYNDROME
Clinical trials for PRIMARY ANTIPHOSPHOLIPID SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PRIMARY ANTIPHOSPHOLIPID SYNDROME trials appear
Sign up with your email to follow new studies for PRIMARY ANTIPHOSPHOLIPID SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame rare clotting disorder
Disease control Recruiting nowThis study tests the safety of an experimental drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections of the drug for up to 52 weeks, alongside …
Matched conditions: PRIMARY ANTIPHOSPHOLIPID SYNDROME
Phase: PHASE2 • Sponsor: National and Kapodistrian University of Athens • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a cancer drug tame rare clotting disorder?
Disease control Recruiting nowThis study tests whether daratumumab, a drug used for certain cancers, is safe for people with antiphospholipid syndrome (APS), an autoimmune disorder that raises blood clot risk. Up to 22 adults will receive weekly infusions for 8 weeks at different doses. The main goal is to ch…
Matched conditions: PRIMARY ANTIPHOSPHOLIPID SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC